StockNews.com began coverage on shares of TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report published on Sunday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright reissued a neutral rating on shares of TRACON Pharmaceuticals in a report on Monday, July 1st.
Check Out Our Latest Research Report on TRACON Pharmaceuticals
TRACON Pharmaceuticals Stock Performance
TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.94) EPS for the quarter. The firm had revenue of $0.06 million for the quarter.
TRACON Pharmaceuticals Dividend Announcement
The business also recently declared a dividend, which was paid on Monday, July 8th. Stockholders of record on Friday, June 28th were paid a $0.045 dividend. The ex-dividend date was Thursday, June 27th. This represents a dividend yield of 40.3%.
TRACON Pharmaceuticals Company Profile
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications.
Featured Stories
- Five stocks we like better than TRACON Pharmaceuticals
- Why Are These Companies Considered Blue Chips?
- Study: How Much Are Retirees Earning from Side Hustles in 2024?
- How Investors Can Find the Best Cheap Dividend Stocks
- Brinker International Offers a Pullback Opportunity on EPS Miss
- Which Wall Street Analysts are the Most Accurate?
- Globant Is an Emerging AI Play That’s Expanding Its Footprint
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.